A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat withPembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Study of Telaglenastat in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Calithera Biosciences
Enrolling: Male and Female Patients
IRB Number: AAAT1473
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine the amount (dose) of telaglenastat that is safe and tolerable when given together with the recommended treatment regimen of pembrolizumab, carboplatin, and pemetrexed and to determine if the combination of standard drugs with telaglenastat is more active against non-small cell lung cancer (NSCLC) than the standard drugs alone. A placebo, which is a tablet containing no telaglenastat medication, but looks identical to telaglenastat will also be used in this study. Telaglenastat is an investigational drug designed to stop cancer from growing by blocking the activity of a protein called glutaminase. The combination of pembrolizumab, carboplatin, and pemetrexed drugs is a recommended treatment for your type of cancer in medical guidelines. Pemetrexed and carboplatin are approved chemotherapy drugs that treat cancer by damaging the cancer cells. These drugs are given together because in combination they are more effective than each drug is individually. This study is a randomized study, meaning you will have a 50% chance of being placed on the study arm that receives plus standard-of-care drugs or you will be placed on the arm that receives telaglenastat.
This study is closed
Brian Henick, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have a life expectancy of at least 3 months? Yes No
Do you have stage IV non-small cell lung cancer? Yes No
Are you able to swallow oral medication? Yes No
Are you willing and able to take folic acid or vitamin B12? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator